Lv1
80 积分 2025-08-26 加入
IL-33, inflammation and mucus in COPD: the final FRONTIER?
5天前
已完结
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
10天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
3个月前
已完结
Adjuvant Immunotherapy in Lung Cancer
6个月前
已关闭
Towards a personalized utilization of stereotactic body radiotherapy for the management of liver metastases in solid tumors
7个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
7个月前
已完结
Phase separation of RXRγ drives tumor chemoresistance and represents a therapeutic target for small-cell lung cancer
8个月前
已完结
Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study
9个月前
已完结
皖公网安备34019202002308
